Product pipeline
Vectura has an innovative and broad clinical pipeline that combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors.
The respiratory pipeline comprises inhaled formulations of both branded and generic products for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).
In the neurological area, Vectura is exploiting its pulmonary delivery technology for indications such as Parkinson’s disease and migraine, and is exploring additional opportunities for future development.
For other indications, Vectura has invested in the development of products for sexual dysfunction and diabetes. Whilst these are not areas of in-house development focus for Vectura, they present significant licensing opportunities.
